Diethylstilbestrol (DES): Understanding the Risks and History
Diethylstilbestrol (DES) – A Historical Tragedy
DES is a synthetic estrogen prescribed 1940s–1971 to prevent miscarriage. In 1971, FDA withdrew it after linking prenatal exposure to:
- Clear cell adenocarcinoma of vagina/cervix in "DES daughters" (rare but devastating).
- Reproductive tract anomalies (T‑shaped uterus, infertility).
- Increased breast cancer risk in mothers who took it.
DES is no longer used in pregnancy. Exposed individuals should inform providers for appropriate screening (e.g., annual vaginal/cervical exams for daughters).
Medical Billing - Related Articles
- US Medical Assistant Programs: Are They Legitimate? A Detailed Review
- HMO Financial Audits: A Comprehensive Guide for Providers
- Understanding Medical Terminology: A Beginner's Guide
- Accounting for Patient Deposits: Unearned Revenue Recognition
- Patient Access to Medical Records: Rights and How to Request
- Mathematics in Medicine: 10 Essential Applications for Physicians
- Medical Coding vs. Billing: Understanding the Key Differences
